CHMP Adopts Positive Opinion Recommending Hepcludex® for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus Life Science Investing News
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Pharmaceutical Investing
Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering Pharmaceutical Investing
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® For Adults with Active Lupus Nephritis Pharmaceutical Investing
RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis , now available across Canada Pharmaceutical Investing
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual General Meeting Life Science Investing News
Albert Labs Receives preliminary acceptance of 35 Novel Inventive Claims for Patent Protected Manufacturing Technology Pharmaceutical Investing
